Voglibose

DB04878InvestigationalSmall molecule

Voglibose is an alpha-glucosidase inhibitor indicated in the management of postprandial blood glucose in patients with type II diabetes. It is made in India by Ranbaxy Labs and sold under the trade name Volix.

Chemical structure of Voglibose
Mechanism
Curator reviewed
Primary indication
For the treatment of diabetes.Curator reviewed · 4 structured indications
Formula / weight
C10H21NO7 · 267.2762 g/mol (avg)
Code names
A-71100 · AO-128

Resolves to

Structure
InChIKeyFZNCGRZWXLXZSZ-CIQUZCHMSA-NSMILESOCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Targets

What you can answer from here — as of June 19, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
610Drug interactionsStructured to mechanism, not free text
Sign in
12Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
8ContraindicationsEach with its own population and attribute set
Sign in
7Marketed productsAcross 2 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 14 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Voglibose, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account